Inflammation in the lungs is a hallmark of chronic obstructive pulmonary disease (COPD) (1) (2) (3) , and inflammatory cells remain elevated in the lungs of patients with COPD long after smoking cessation (4) (5) (6) . Although innate immune cells, such as neutrophils and macrophages, are critical for pathogen eradication during acute infection, evidence from animal models suggests that proteases produced by these cells may overwhelm endogenous antiproteases and injure the lung, resulting in emphysematous destruction of alveolar tissue (7, 8) .
Recent evidence suggests that localized loss of secretory IgA (SIgA) in small airways may play an important role in COPD progression after smoking cessation (2, 9, 10) . SIgA normally lines mucosal surfaces throughout the body where it agglutinates bacteria and other antigens, facilitating their clearance by the mucociliary escalator and preventing activation of inflammatory signaling cascades in epithelial cells through immune exclusion (11) (12) (13) . Consistent with a role in airway defense, loss of airway surface SIgA in individual small airways in lungs of patients with COPD is associated with markers of latent viral reactivation, bacterial invasion into the mucosa, NF-kB activation in airway epithelial cells, and accumulation of immune/inflammatory cells (2, 10) . Similar findings occur in the lungs of polymeric Ig receptor null (pIgR 2/2 ) mice, which lack SIgA in the airways and develop fibrotic remodeling of small airways and emphysema with aging (14) .
In these studies, we sought to investigate the role of neutrophils in determining small airway pathology and emphysema in SIgA-deficient (pIgR 2/2 ) mice. We found that chronic neutrophilic inflammation develops as a consequence of pIgR deficiency and contributes to small airway fibrosis and emphysema. Furthermore, we showed that bacterial products are the primary stimulus for neutrophilic inflammation in pIgR 2/2 mice. These data help to define the mechanisms of persistent inflammation in COPD, and suggest that impaired mucosal immunity in the airways results in airway wall remodeling and emphysematous destruction of the adjacent alveolar compartment.
Methods
Additional material and methods information is provided in the data supplement.
Animal Model pIgR
2/2 mice, backcrossed onto a C57Bl/6 background for a minimum of eight generations (15) , were obtained from the Mutant Mouse Resource Research Center at the University of Missouri. Wild-type (WT) and pIgR 2/2 mice were housed in standard microisolator cages in a centralized animal care facility and provided food and water ad libitum. All procedures involving mice were approved by the Institutional Care and Use Committee of Vanderbilt University.
Morphometry
Airway wall remodeling was assessed by morphometric evaluation of small airway wall thickness, as previously described (1, 2) . Emphysematous changes of lung parenchyma were quantified using alveolar septal perimeter measurements on 10 randomly chosen fields of alveolar tissue at 2003 magnification, according to American Thoracic Society recommendations (16) . For measurement of collagen content in the lamina propria of small airways, we measured the area occupied by collagen content (based on picosirius red staining) divided by the length of the basement membrane in small airways. For quantification of elastin in the alveolar compartment, elastin immunofluorescence was evaluated on five consecutive fields of lung parenchyma (captured at 340 objective) and quantified as actual pixel counts per field (airspace normalized to zero). All morphometric measurements were made using Image-Pro Plus software (Media Cybernetics).
Neutrophil Depletion 100 mg of anti-Ly6G antibodies (Clone 1A8, cat. BP0075-1) from BioXCell (West Lebanon, NH) or rat IgG2a isotype control antibodies (BioXCell) were delivered by intraperitoneal injection twice weekly for 16 weeks as previously described (17) .
Antibiotics Administration
Vancomycin (0.5 mg/ml), neomycin (1 mg/ml), ampicillin (1 mg/ml), and metronidazole (1 mg/ml) (VNAM) were dissolved in autoclaved drinking water and provided to animals ad libitum for 3 months. Water was changed twice weekly. Control animals received autoclaved water only.
Nebulization Treatments

WT or pIgR
2/2 mice were placed in a whole-body nebulization chamber (inExpose; Scireq) and exposed to 10 mg of bacterial lysate aerosolized by a 5 L/min pump. Control animals were treated with nebulized sterile PBS. Mice were treated with nebulized bacterial lysates once weekly for 4 months. All animals were harvested 4 days after the final nebulization treatment.
Roflumilast Administration
A 200-ml aliquot of 0.5 mg/ml suspension of roflumilast or vehicle (4% methylcellulose, 1.3% polyethylene glycol 400, z5 mg drug/mg animal weight) was administered by oral gavage once daily, 5 d/wk for the duration of treatment, as previously described (14) . The roflumilast suspension was freshly prepared each week and stored at 4 8 C.
Statistical Analysis
Mice were randomly assigned to the study groups and, where possible, researchers were blinded to the study groups until the time of statistical analysis. All animals were included in each analysis. Error bars reflect mean (6SEM). Pair-wise comparisons were made using t tests, whereas multiple comparisons were made using two-way 
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2 ) in pIgR 2/2 mice compared with age-matched WT controls ( Figures 1A and 1B) . The percentage of neutrophils among CD45 1 immune/ inflammatory cells was also increased in pIgR 2/2 mice, but there was no difference in the percentage of alveolar macrophages ( Figures 1C and 1D) .
Next, we investigated the relationship between inflammation and lung remodeling in pIgR 2/2 mice using stains for elastin and collagen, as well as transmission electron microscopy. As shown in Figure 2A , 12-month-old pIgR 2/2 mice developed marked emphysemous destruction of the distal lung parenchyma. Consistent with evidence of emphysema on hematoxylin and eosin staining, we found that elastin content was markedly reduced in interalveolar septae of pIgR 2/2 mice ( Figures 2B  and 2C ). In addition, transmission electron microscopy micrographs showed increased lucency of the interalveolar septum, suggesting extracellular matrix degradation in pIgR 2/2 mice ( Figure 2D , red stars).
In the small airways of 12-month-old pIgR 2/2 mice, we observed thickening of the airway wall and increased collagen deposition in the lamina propria compared with age-matched WT mice ( Figures  3A-3D ). Despite increased collagen deposition, elastin destruction and reduced elastin content was observed in small airways of pIgR 2/2 mice ( Figure 3E ). Together, these data indicate that lungs of pIgR 2/2 mice are characterized by diffuse elastin degradation and fibrotic remodeling of small airway walls in association with neutrophil accumulation.
Because destructive changes in the lungs of pIgR 2/2 mice were present in both small airways and lung parenchyma, we sought to determine whether these pathological changes were a direct result of localized pIgR deficiency or occurred as a consequence of loss of pIgR only in small airways. By immunostaining, pIgR was readily observable in the airway epithelium, where it could be seen in close proximity to SIgA on the airway surface; however, pIgR expression was not identified in alveolar tissue ( Figure E2A ). In vitro, murine tracheal epithelial cells grown in air-liquid interface culture to stimulate differentiation had robust pIgR expression, as determined by immunostaining, which colocalized with a-tubulin expression in multiciliated cells ( Figure E2B ). In addition, PIGR mRNA expression was significantly higher in To determine whether neutrophilic inflammation plays an important role in lung remodeling in pIgR 2/2 mice, we treated pIgR 2/2 mice via intraperitoneal injection with anti-neutrophil-specific antibodies (anti-Ly6G, clone 1A8) (18) or rat isotype control IgG twice weekly for 4 months, according to a protocol previously shown to reduce neutrophil numbers in the lung (17) . Compared with treatment with isotype control IgG, pIgR 2/2 mice treated with anti-Ly6G antibodies had a fivefold reduction in parenchymal neutrophil numbers ( Figure 4A ), as well as decreased neutrophil elastase and total elastase activity in lung lysates (Figures 4B-4D) . These mice displayed a marked reduction in fibrotic remodeling around small airways and emphysema in the lung parenchyma as assessed by morphometric evaluation (Figures 4E and 4F) .
Next, we wondered whether airway bacteria were responsible for the neutrophil influx that contributes to small airway wall remodeling and emphysema in pIgR 2/2 mice. For these studies, we treated pIgR 2/2 mice for 3 months with a broad-spectrum antibiotic cocktail (VNAM) dissolved in drinking water, which has previously been shown to reduce endogenous bacterial flora in mice (19) . pIgR 2/2 mice treated with the VNAM cocktail showed a reduction in the percentage of airways with bacterial invasion across epithelial barrier, indicating that the VNAM regimen partially depleted endogenous airway bacteria ( Figures 5A and 5B). Reduced bacterial burden was associated with reduced numbers of neutrophils in the lung parenchyma and reduced total elastase activity ( Figures 5C  and 5D ). Treatment with the VNAM cocktail led to significant reductions in small airway wall thickening and emphysema ( Figures 5E and 5F ). Together with our previous study (14) , these data strongly implicate airway bacteria as a key driver of lung remodeling in this model. Patients with COPD may develop acute worsening of respiratory symptoms due to bacterial infection or acquisition of a new bacterial species (20, 21) , and these exacerbations are associated with increased inflammation (22) (23) (24) (25) . To investigate whether loss of SIgA in the airways contributes to increased inflammation and lung remodeling in response to a bacterial challenge, we adapted a previously reported model using repetitive nebulization with nontypeable Haemophilus influenzae (NTHi) (26) , which is the most common bacterium isolated during COPD exacerbations (27) . We found that a single dose of nebulized NTHi lysate resulted in a significant accumulation of neutrophils and increased macrophages in BAL fluid after 24 hours in WT mice ( Figures E3A and  E3B) . We then treated 2-month-old WT or pIgR 2/2 mice with NTHi lysate via nebulization once weekly for 16 weeks. After NTHi treatment, we observed significantly higher cell counts in BAL fluid, including both neutrophils and macrophages, from pIgR 2/2 mice compared with WT mice (Figures 6A-6C ). As shown in Figures 6D-6G , NTHi treatment exacerbated fibrotic thickening of the small airway walls and caused emphysematous parenchymal destruction in both WT and pIgR 2/2 mice. Among all groups, emphysema was most severe in NTHi-treated pIgR 2/2 mice and small airway wall thickening tended to be most severe in NTHi-treated pIgR 2/2 mice (P = 0.05 compared with NTHi-treated WT mice).
Bacterial LPS is a major constituent of outer membrane of gram-negative bacteria, such as NTHi, and repetitive exposure to LPS has previously been shown to cause emphysema in mice (28) . To determine whether bacterial products other than LPS 
(t test). (B)
Western blot and (C) densitometry for neutrophil elastase (NE; 26 kD) in lung tissue, normalized to b-actin; n = 6-7 mice/group; *P , 0.001 (t test). (D) Elastase activity in whole-lung lysates; n = 4-5 mice/group; *P , 0.05 (t test). (E) Morphometric analysis of small airway wall thickness (V V airway ); n = 8-9 mice/group; *P , 0.01 (t test). (F) Morphometric analysis of emphysema (mean alveolar septal perimeter); n = 8-9 mice/group; *P , 0.0001 (t test).
could augment inflammatory responses and lung remodeling in pIgR 2/2 mice, we treated mice with lysates prepared from the nonpathogenic, gram-positive organism, Bacillus badius, once weekly for 16 weeks. In these studies, we found that pIgR 2/2 mice treated with B. badius lysates had higher levels of neutrophils in BAL and more severe airway wall fibrosis and emphysema than similarly treated WT mice ( Figure E4 ). Together, these data indicate that exogenous bacterial challenge can further exacerbate small airway fibrosis and emphysema in pIgR 2/2 mice. Roflumilast is a phosphodiesterase-4 inhibitor that has been shown to decrease neutrophilic inflammation in animal models of COPD (29) , and can reduce exacerbations in patients with severe disease and symptoms of chronic bronchitis (30) . To determine whether roflumilast protects pIgR 2/2 mice from NTHi-induced inflammation and lung remodeling, we treated pIgR 2/2 mice daily by oral gavage with 100 mg of roflumilast (5 mg/g) or vehicle (5% methylcellulose, 1.3% polyethylene glycol 400) for 4 months concurrent with weekly NTHi nebulization. Roflumilast treatment significantly reduced the number of BAL cells, both neutrophils and macrophages, in pIgR 2/2 mice after repetitive NTHi lysate treatment (Figures 7A-7C ). Relative to animals treated with vehicle, roflumilast treatment resulted in significant reductions in both small airway wall fibrosis and emphysema ( Figures 7D and 7E ). These data indicate that exaggerated inflammation drives lung remodeling in pIgR 2/2 mice after repetitive exposure to bacterial products.
Discussion
These studies demonstrate that, in a murine model of SIgA deficiency, neutrophils accumulate in the lung and promote injury and remodeling of small airways and alveolar parenchyma. Treatment with broad-spectrum antibiotics reduces numbers of neutrophils in the lungs and inhibits small airway and parenchymal remodeling, implicating airway bacteria as the primary driver of these COPD-like phenotypes in the lungs of pIgR 2/2 mice. Conversely, exposure to exogenous bacterial products from pathogenic and nonpathogenic bacteria amplifies inflammation and remodeling above that caused by endogenous bacteria. Treatment with the antiinflammatory drug, roflumilast, blocks inflammatory cell recruitment and remodeling in pIgR 2/2 mice, suggesting that neutrophil-derived proteases, rather than bacterial products per se, are the stimulus for small airway wall fibrosis and emphysema in these mice. Together, these data show that airway bacteria drive chronic neutrophilic inflammation and progressive lung destruction in pIgR 2/2 mice where the mucosal immune barrier is compromised.
Neutrophilic inflammation is a hallmark of COPD (1, (31) (32) (33) , and neutrophils are known to contribute to lung destruction in cigarette smoke-exposed mice (8) . This shows that neutrophils also accumulate in the lungs of pIgR 2/2 mice, which lack SIgA in the lung and develop small airway and parenchymal remodeling independent of cigarette smoke exposure (14) . We found that increased numbers of neutrophils in the lungs of pIgR 2/2 mice are associated with decreased elastin content in small airways and the lung parenchyma, consistent with elastin degradation by neutrophil-derived proteases. In addition to elastin breakdown, we observed increased collagen deposition around the airways of pIgR 2/2 mice similar to the small airways of patients with COPD (1). In vivo neutrophil depletion using neutrophil-specific antibodies protected pIgR 2/2 mice from small airway remodeling and emphysema, providing direct evidence that neutrophils promote lung pathology in this model. Given that SIgA is known to be widespread in the airways of patients with COPD (2, 9, 10), our work suggests that loss of SIgA in the airways of former smokers with COPD drives chronic neutrophilic inflammation, protease-antiprotease imbalance, and ongoing injury and remodeling of small airways and alveolar tissue. Under basal conditions in WT mice, we found robust expression of pIgR in the airway epithelium, but minimal expression of pIgR in the alveolar epithelium. This finding suggests that an impaired mucosal immunobarrier in the small airways initiates a pathologic cycle of inflammation and protease production that ultimately damages both the small airways and the lung parenchyma. These data provide a potential biologic explanation for the observation that small airways disease precedes the development of emphysema in many patients, and that emphysematous lung destruction is most severe near terminal bronchioles (34, 35) . Although our studies suggest that neutrophils are a key mediator of lung damage in SIgA-deficient airways, these data do not exclude contributions from other cell types. Macrophages are also increased in the lungs of patients with COPD (1, 10) , and elastase and matrix metalloproteinase production by these cells is known to contribute to emphysema in animal models (7, 36) . Further investigation into a role for macrophages in lung destruction in pIgR 2/2 mice is warranted. In addition, loss of SIgA may activate the adaptive immune system, which could potentiate lung damage through direct cytolytic effects, by stimulating epithelial cell apoptosis or by augmenting innate immune responses.
Multiple studies have suggested that airway bacteria play a role in COPD progression (20, (37) (38) (39) . We previously reported that loss of SIgA in small airways is associated with increased bacterial invasion into the airway mucosa, and that 2/2 mice raised in germ-free conditions are protected from the lung remodeling phenotype (10) . Here, we show that broad-spectrum antibiotic treatment ameliorates neutrophilic inflammation and lung remodeling in pIgR 2/2 mice, providing additional evidence that airway bacteria drive lung remodeling in this model. Despite these findings, it is unlikely that long-term antibiotics would be effective as a therapeutic strategy in COPD.
Expression of pIgR is regulated by the presence of airway bacteria (40, 41) , and thus suppression of endogenous bacteria with antibiotics might paradoxically suppress pIgR expression and SIgA transcytosis. Furthermore, some bacteria are known to degrade SIgA (19, (42) (43) (44) , and alterations in bacterial community structure induced by antibiotics could favor outgrowth of SIgA-degrading bacteria.
Exposure to NTHi or B. badius lysates resulted in more severe neutrophilic inflammation and lung remodeling in pIgR 2/2 mice. This finding indicates that loss of SIgA may result in an exaggerated inflammatory response to bacteria, consistent with observations in patients with COPD (45) . Furthermore, these data may help explain the observation that frequent COPD exacerbations, which are often caused by bacteria (20) , are associated with an accelerated rate of decline in forced expiratory volume in 1 second (37) . Our studies, therefore, provide additional rationale for aggressive pharmacotherapy to reduce exacerbations, as recommended by current GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines (46) . In addition, we found that treatment with roflumilast could ameliorate neutrophilic inflammation and lung remodeling in pIgR 2/2 mice treated with NTHi lysates. Roflumilast is known to reduce numbers of inflammatory cells, including neutrophils and macrophages, in the lungs of cigarette smoke-exposed mice (29) . Our study provides additional evidence supporting the use of this treatment to reduce exacerbations in patients with COPD.
Together, our data support the conclusion that loss of SIgA results in chronic neutrophilic inflammation that contributes to progressive small airway fibrosis and emphysema. In the future, strategies aimed at reducing chronic inflammation or restoring the normal SIgA immunobarrier in patients with COPD may be useful to slow disease progression. n . Roflumilast treatment inhibits inflammation and blocks lung remodeling in pIgR 2/2 mice after repetitive exposure to NTHi lysate. pIgR 2/2 mice were treated by oral gavage with daily roflumilast or vehicle (Veh) concurrent with weekly NTHi nebulizations from 2 to 6 months of age. (A-C) Total cells, neutrophils, and macrophages in BAL fluid; n = 6-7 mice/group; *P , 0.05 (t test). (D) Morphometric analysis of small VV airway ; n = 5 mice/group; *P , 0.01 (t test). (E) Morphometric analysis of emphysema (mean alveolar septal perimeter); n = 5 mice/group; *P , 0.0001.
